ReviewCurrent rheumatology reports2025
The Role of FDG-PET in the Diagnosis and Monitoring of Large-Vessel Vasculitis.
Review in Current rheumatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Differential Vascular Response to Corticosteroid Therapy in Takayasu Arteritis Revealed by Serial FDG-PET Imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026Review
- Prevalence and characteristics of coronary arteritis within a prospective observational cohort of patients with Takayasu's arteritis.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of this reviewGiant cell arteritis (GCA) and Takayasu's arteritis (TAK) are the two main forms of large-vessel vasculitis (LVV), defined by inflammation of the aorta and its primary branches. Use of vascular imaging, including FDG-PET, has been increasingly incorporated into the assessment of patients with LVV. FDG-PET detects metabolic activity in the walls of the large arteries as a surrogate for vascular inflammation. In this article we review the use of FDG-PET to diagnose and monitor disease activity in different forms of LVV. RECENT
findingsUse of FDG-PET to diagnose GCA by assessing vascular FDG uptake in the aorta and branch arteries is well-established. More recently, newer generation PET/CT scanners have also been used to assess metabolic activity in the cranial arteries, including the temporal arteries. In TAK, non-invasive angiography is used to assess for luminal damage at diagnosis, while FDG-PET can provide complementary information about whether active vascular inflammation is present. Recent studies have focused on the use of FDG-PET to monitor disease activity in LVV and the prognostic value of FDG-PET scans. Use FDG-PET in LVV remains an area of active ongoing research. While use at time of diagnosis in LVV has become well established, more studies are needed to evaluate the prognostic value of FDG-PET when monitoring disease activity in patients with LVV. Additional future directions for use of FDG-PET in LVV include employment of novel radiotracers, use of newer generation PET scanners, and incorporation into clinical trials to assess treatment response at the vascular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.